These results demonstrate superior performance compared to other GLP-1 agonists, insulin, and placebo [23, 24, 25, 26]
In other words, at the end of 88 weeks, those who continued taking tirzepetide had lost on average 60 pounds, and those who went on the placebo maintained a 22-pound weight loss
When starting both, it may be difficult to determine which medication is causing the side effect
Yes, many patients successfully transition to Tirzepatide if they experience a weight loss plateau or require better appetite control
Your report helps improve the safety of medicines for everyone
Liquid chromatography tandem mass spectrometry can identify and quantify peptides in plasma or urine